Hepatitis C: Life-threatening barriers in access to breakthrough drugs in US

29 junio 2015

Most states violate federal Medicaid law because they deny coverage for sofosbuvir, a new and highly effective treatment to cure hepatitis C. According to a team of researchers who examined Medicaid policies for hepatitis C virus treatment using sofosbuvir, more commonly known as Solvadi, most should change policy to improve access to the treatment.